SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.070
-0.030 (-0.97%)
At close: Nov 10, 2026, 4:00 PM EST
3.030
-0.040 (-1.30%)
After-hours: Nov 10, 2026, 4:37 PM EST

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
277178356330340
Market Cap Growth
96.17%408.46%-44.79%113.36%-91.25%-
Enterprise Value
1777396627336
Last Close Price
3.073.743.796.885.9078.10

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-41.78----
PS Ratio
--26.4828.331.245.58
PB Ratio
1.331.181.351.110.968.81
P/TBV Ratio
1.311.181.351.110.968.81
P/OCF Ratio
-----170.89

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
--6.9129.321.145.51

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.020.040.180.100.190.22
Net Debt / Equity Ratio
-0.47-0.60-0.62-0.88-0.29-0.64
Net Debt / EBITDA Ratio
1.211.980.421.480.362.07
Net Debt / FCF Ratio
1.691.980.472.000.362.76
Asset Turnover
--0.020.030.360.88
Quick Ratio
7.139.132.615.231.371.56
Current Ratio
7.289.462.985.451.471.90
Return on Equity (ROE)
-42.83%14.96%-81.92%-95.51%-53.85%-44.21%
Return on Assets (ROA)
-25.37%-28.20%-41.86%-35.30%-27.37%-12.16%
Return on Capital Employed (ROCE)
-38.50%-30.20%-118.50%-52.10%-80.50%-24.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-48.46%7.46%-97.39%-66.52%-63.04%-5.05%
FCF Yield
-21.24%-25.67%-98.89%-39.91%-86.20%-2.64%
Buyback Yield / Dilution
-613.70%-562.28%-67.74%-26.86%-59.20%-1.21%
SEC Filings: 10-K · 10-Q